TickerFacts.

Compare

Akebia Therapeutics, Inc. vs Keros Therapeutics, Inc. vs Puma Biotechnology, Inc. vs IDEAYA Biosciences, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearAkebia Therapeutics, Inc.
AKBA		Keros Therapeutics, Inc.
KROS		Puma Biotechnology, Inc.
PBYI		IDEAYA Biosciences, Inc.
IDYA
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$236.20M$244.06M$228.37M$218.71M
Revenue growth (YoY)+47.5%n/m-0.9%n/m
Gross margin83.3% (computed)n/a74.5% (computed)n/a
Operating margin9.9%27.7%16.3%-72.8%
Net margin-2.3%35.7%13.6%-52.0%
Net income-$5.34M$87.01M$31.11M-$113.70M
EPS (Diluted)-$0.02$2.30$0.61-$1.28
Operating cash flow$67.99M$107.50M$41.80M-$71.10M
Free cash flow$67.70M$105.95M$41.73M-$73.47M
Cash & equivalents$184.84M$287.42M$29.64M$112.83M
Total assets$376.56M$338.02M$216.30M$1.11B
Total liabilities$343.95M$34.89M$85.96M$86.39M
Shareholders' equity$32.61M$303.13M$130.34M$1.02B
Return on year-end equity-16.4%28.7%23.9%-11.1%
Shares outstanding265.42M19.54M50.41M87.80M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearAkebia Therapeutics, Inc.Keros Therapeutics, Inc.Puma Biotechnology, Inc.IDEAYA Biosciences, Inc.
Latest$236.20M
Ended 2025-12-31		$244.06M
Ended 2025-12-31		$228.37M
Ended 2025-12-31		$218.71M
Ended 2025-12-31
1 year earlier$160.18M
Ended 2024-12-31		$3.55M
Ended 2024-12-31		$230.47M
Ended 2024-12-31		$7.00M
Ended 2024-12-31
2 years earlier$194.62M
Ended 2023-12-31		$151.0K
Ended 2023-12-31		$235.64M
Ended 2023-12-31		$23.39M
Ended 2023-12-31
3 years earlier$292.48M
Ended 2022-12-31		$0
Ended 2022-12-31		$228.03M
Ended 2022-12-31		$50.93M
Ended 2022-12-31
4 years earlier$211.65M
Ended 2021-12-31		$20.10M
Ended 2021-12-31		$253.16M
Ended 2021-12-31		$27.94M
Ended 2021-12-31